A r t i c l e s NR4A1 (Nur77), NR4A2 (Nurr1) and NR4A3 (NOR-1) constitute the NR4A subfamily of orphan nuclear receptors in the steroid thyroid receptor family 1 . NR4A1 was originally identified as being encoded by a growth factor-inducible gene and is often overexpressed in a variety of cancer cells, including lung, prostate, breast and colon cancers [2] [3] [4] [5] . Many growth factors and mitogens rapidly induce NR4A1 expression, which suggests a survival role for this molecule in mediating the growth of cancer cells. Conversely, NR4A1 has been linked to the programmed cell death of T lymphocytes and B lymphocytes 6, 7 . NR4A1 is rapidly induced by T cell antigen receptor signals, and dominant-negative NR4A1 inhibits the clonal deletion of developing T cells, which indicates a role for NR4A1 and its family members in thymocyte negative selection [8] [9] [10] . Nr4a1 mRNA is also rapidly (<1 h) and potently induced in macrophages in response to a variety of inflammatory stimuli, including lipopolysaccharide, cytokines and oxidized lipids 11 .
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Structural and functional studies of NR4A1 and other members of the NR4A family suggest that these nuclear receptors do not need to bind small-molecule ligands to be activated 12, 13 . Instead, they seem to be regulated mainly by post-translational modifications, such as phosphorylation 14 . Acting as a transcription factor, NR4A1 can directly bind specific DNA-response elements alone or can form heterodimers with the retinoid X receptor 15, 16 . In response to apoptotic stimuli, NR4A1 may form a dimer with retinoid X receptor and translocate from the nucleus to the cytoplasm, where it can target mitochondria to induce the release of cytochrome c and apoptosis 17 . Consistent with its role as a mediator of apoptosis in lymphocytes, NR4A1 triggers mitochondrial apoptosis though its interaction with Bcl-2, converting Bcl-2 from an antiapoptotic molecule to a proapoptotic molecule 18, 19 .
Little is known about the exact functions of NR4A1 in monocyte biology. Of clinical relevance, NR4A1 is located in macrophages in human atherosclerotic lesions and diminishes the loading of lipids into macrophages and their inflammatory responses 20, 21 . NR4A1 also inhibits the accumulation of macrophages and vascular remodeling in mice 22 . Nr4a3 −/− Nr4a1 −/− mice develop acute myeloid leukemia with abnormal population expansion of myeloid progenitor cells 23 . Studies of NR4A3 and NR4A1 in hypoallelic (Nr4a3 +/− Nr4a1 −/− and Nr4a3 −/− Nr4a1 +/− ) mice have shown that they recapitulate the pathological features of myelodysplastic-myeloproliferative neoplasms, with enhanced proliferation and excessive apoptosis of hematopoietic stem cells and myeloid progenitors 24 . However, mice deficient in either NR4A1 or NR4A3 have relatively subtle abnormalities and lack overt defects in general physiology, consistent with the idea that NR4A family members have some functional redundancy 25 . Notably, NR4A2, a closely related member of the NR4A family, has been shown to have a regulatory role in maintaining the quiescence of hematopoietic stem cells 26 . Such work has demonstrated an important role for members of the NR4A family of nuclear receptors in myeloid differentiation and inflammatory diseases.
In mice and humans, at least two distinct subsets of CD11b + CD115 + blood monocyte exist. In mice, Ly6C + CCR2 + CX3CR1 lo CD62L + monocytes are recruited to inflamed or infected tissues and lymph nodes [27] [28] [29] and can differentiate into antigen-presenting cells that A r t i c l e s produce tumor necrosis factor, nitric oxide and reactive oxygen species 30, 31 . Ly6C − CCR2 lo CX3CR1 hi CD62L − monocytes patrol the resting vasculature and can populate inflamed sites 28, 32, 33 . Ly6C + mouse monocytes are analogous to CD14 + human monocytes, which show a strong inflammatory response to lipopolysaccharide, and Ly6C − mouse monocytes are most probably analogous to CD14 lo CD16 + human monocytes, which patrol blood vessels and develop a proinflammatory response consisting of tumor necrosis factor and interleukin 1β that is induced by a Toll-like receptor 7-adaptor MyD88-MEK kinase pathway 34 . Both populations of monocytes are recruited to sites of inflammation or injury 32, 35, 36 . Both Ly6C + monocytes 37 and Ly6C − monocytes 35 can also participate in the resolution of inflammation and tissue repair.
Monocyte subsets arise from a common macrophage dendritic precursor (MDP) in the bone marrow 38 . However, the details of the differentiation steps and intermediaries between MDPs and mature monocyte subsets in the bone marrow are unclear. Adoptive-transfer experiments have shown that Ly6C + monocytes can downregulate Ly6C expression and move between blood and bone marrow [39] [40] [41] , but whether the loss of Ly6C expression corresponds to the conversion of one monocyte subset into another has been questioned 42 . Many transcription factors, including PU.1, JunB, C/EBP-α, C/EBP-β and IRF8, have important roles in myeloid-lineage differentiation, but the specific factors that drive the differentiation of Ly6C − monocytes are unknown 38 . Here we sought to identify previously unknown transcription factors that control the differentiation of monocyte subsets in vivo. We identified an absence of Ly6C − monocytes arising from NR4A1-deficient MDP cells in the bone marrow. Ly6C − monocytes remaining in the bone marrow of NR4A1-deficient mice underwent apoptosis because of abnormal cell-cycle progression, which indicated a critical role for NR4A1 in the differentiation and survival of Ly6C − monocytes.
RESULTS

NR4A expression in monocytes and progenitors
We first examined the expression of mRNA for NR4A1 and other members of the NR4A family in Ly6C + and Ly6C − monocytes and myeloid progenitor populations in the bone marrow of wild-type (C57BL/6J) mice (Fig. 1a) . Ly6C − monocytes expressed on average sevenfold more Nr4a1 mRNA than did Ly6C + monocytes, MDPs or common myeloid precursors (Fig. 1a) . Similarly, NR4A1 protein expression was highest in Ly6C − monocyte populations (Fig. 1b) . NR4A1 protein expression was much higher in monocyte populations than in nonmyeloid (CD11b − ) cells (Fig. 1b) . Nr4a2 mRNA was also expressed in monocytes and myeloid progenitor cells, whereas Nr4a3 mRNA expression was undetectable (Fig. 1a) . Notably, Nr4a2 mRNA expression was highest in MDPs, which are the precursors to monocytes, but it was less abundantly expressed in differentiated monocyte populations (Fig. 1a) . We confirmed that expression of NR4A1 distinguished Ly6C − 'patrolling' monocytes from Ly6C + 'inflammatory' monocytes with a new transgenic reporter mouse model in which induction of the Nr4a1 promoter drives expression of green fluorescent protein (NR4A1-GFP). The majority of CD11b + F4/80 + Ly6C neg−lo monocytes (over 85%) circulating in the blood (Fig. 1c) and spleen (data not shown) of these reporter mice had abundant expression of A r t i c l e s NR4A1-GFP; the majority of Ly6C + monocytes (over 95%) had low although not negligible expression of NR4A1-GFP (Fig. 1c) . Notably, as Ly6C expression decreased, NR4A1-GFP expression increased among CD11b + F4/80 + monocytes ( Supplementary Fig. 1 ). GFP hi monocytes in NR4A1-GFP mice had other defining phenotypic features of patrolling monocytes, including abundant expression of the integrin CD11a (LFA-1), low expression of CD62L (L-selectin) and intermediate expression of the common dendritic cell (DC) marker CD11c and, by quantitative PCR, higher expression of the chemokine receptor CX3CR1 and lower expression of the chemokine receptor CCR2 than their Ly6C + counterparts ( Fig. 1d and data not shown).
All GFP hi cells circulating in the blood of NR4A1-GFP mice were F4/80 + CD11b + monocytes and had the horseshoe-shaped nuclear morphology characteristic of monocytes (data not shown). Thus, Ly6C − monocytes had higher expression of NR4A1 than did Ly6C + monocytes or monocyte progenitors, which suggested that NR4A1 may have a unique function in this particular monocyte subset.
Nr4a1 −/− mice lack Ly6C − monocytes Nr4a1 −/− mice had significantly fewer monocytes in bone marrow, blood and spleen than did wild-type (Nr4a1 +/+ ) mice ( Fig. 2a,b ; gating strategies for monocyte subsets in bone marrow, Supplementary  Fig. 2 , and in spleen and blood, Supplementary Fig. 3 ). Monocytes in bone marrow, spleen and blood were identified as cells with low side scatter that were lineage negative (CD19 − CD49b − CD3ε − Ly6G − ) and CD115 + CD11b + . This monocyte population was distinct from DCs identified as CD11c hi CD11b + CD115 − ( Supplementary  Fig. 4a,b) . Furthermore, we observed no difference in the number of CD11c hi DCs in Nr4a1 −/− mice versus wild-type mice ( Supplementary Fig. 4a ). We refined our assessment of the CD115 + CD11b + monocyte population to distinguish between Ly6C + and Ly6C − subsets (Fig. 2a,b) and found that the diminished monocyte population in Nr4a1 −/− mice was due almost entirely to loss of the Ly6C − monocyte population (Fig. 2a,b) . Ly6C − monocytes were missing from the bone . marrow, blood and spleens of Nr4a1 −/− mice (Fig. 2b) . Ly6C + monocyte numbers were also slightly lower in the blood of Nr4a1 −/− mice, although this observation was somewhat variable and not statistically significant. Except for slightly more granulocytes (<10%) in Nr4a1 −/− mice than in wild-type mice, we found little variation in other subsets of cells of the immune response in blood (Fig. 2c) or spleen ( Supplementary Fig. 4a ).
To determine if the defect in Ly6C − monocyte differentiation in Nr4a1 −/− mice was bone marrow derived and cell intrinsic, we engrafted irradiated Nr4a1 −/− or wild-type recipients with Nr4a1 −/− or control wild-type bone marrow (Fig. 3a,b) . Grafting of wild-type bone marrow into Nr4a1 −/− recipients restored the population of Ly6C − monocytes to the normal frequency (Fig. 3b) . However, at 6 weeks after reconstitution of wild-type mice with Nr4a1 −/− bone marrow, we observed 90% fewer Ly6C − monocytes in blood and a more modest 40% fewer Ly6C + monocytes (Fig. 3b) .
Ly6C − monocytes have been shown to patrol the endothelium of blood vessels 28, 32 . Therefore, we investigated the patrolling activity of Nr4a1 −/− monocytes. We transplanted bone marrow from either wild-type or Nr4a1 −/− CD45.2 + mice into irradiated wild-type CD45.1 + recipients (Supplementary Fig. 5 ). Recipients of wild-type bone marrow had a normal frequency of the Ly6C − monocyte subset in the blood (33% ± 1.4%), whereas recipients of Nr4a1 −/− bone marrow had a much lower frequency of the Ly6C − subset (4% ± 1.4%; Supplementary Fig. 5 ). The number of patrolling cells in the blood vessels of the ears of recipients of Nr4a1 −/− bone marrow (1.7 ± 1.3 cells per field per hour) was also much lower than that of mice that received wild-type bone marrow (12 ± 1.5 cells per field per hour; Fig. 3c,d ). Together these data indicate that NR4A1 selectively regulates the production of patrolling Ly6C − monocytes in vivo.
Nr4a1 −/− MDPs do not differentiate into Ly6C − monocytes The number of myeloid progenitor cells, including MDPs, was unaltered in Nr4a1 −/− bone marrow (Fig. 4a) . The Ly6C − monocytes that did appear in the bone marrow of Nr4a1 −/− mice were morphologically larger and seemed less differentiated, with enlarged nuclei that were not horseshoe shaped and with more granularity than that of their counterparts in wild-type mice (Fig. 4b) . It has been hypothesized that both Ly6C + and Ly6C − monocytes arise from MDPs in the bone marrow, but the cellular factors that mediate their specific differentiation are unknown 43 . Our findings suggested that NR4A1 is a factor that regulates the differentiation of Ly6C − monocytes from MDPs in bone marrow.
We did competitive reconstitution experiments to further examine the role of NR4A1 in monocyte development. We mixed bone marrow from CD45.2 + Nr4a1 −/− mice and CD45.1 + wild-type control mice at a ratio of 1:1 and transplanted the mixture into CD45.1 + recipient mice. At 6 weeks after bone marrow transfer, only 25% of Ly6C + monocytes and less than 5% Ly6C − monocytes in spleen (Fig. 5a) or blood (Fig. 5a) were derived from Nr4a1 −/− bone marrow. In contrast, about equal numbers of CD11c hi DCs and all other CD45 + cells were derived from CD45.2 + and CD45.1 + donors (Fig. 5a) . Therefore, Nr4a1 −/− progenitor cells were inefficient specifically in generating monocytes in general and Ly6C − monocytes in particular.
To determine if the expression of NR4A1 in MDPs was required for monocyte differentiation, we did mixed chimeric experiments with MDPs purified by flow cytometry. We mixed isolated MDPs (lineagenegative CD115 + CD117 int cells) from CD45.2 + Nr4a1 −/− mice and CD45.1 + wild-type control mice at a ratio of 1:1 and transplanted the mixture into irradiated CD45.2 + recipient mice. At 7 d after bone marrow transfer, recipients had less than 10% Ly6C − monocytes and 30% Ly6C + monocytes derived from Nr4a1 −/− donors, whereas most monocytes were derived from wild-type donors (Fig. 5b) . These results were similar to those obtained in the bone marrow-transplantation studies (Figs. 3a,b and 5a) . Together the results indicate that NR4A1 expression is required for optimal differentiation of Ly6C − monocytes. These data also suggest that NR4A1 deficiency influences the competitive advantages of Ly6C + monocytes or their precursors, although to a lesser extent than it influences Ly6C − monocytes.
Nr4a1 −/− Ly6C − monocytes accumulate in S phase
Given that other members of the NR4A family have been associated with cell-cycle regulation, we next examined the progression of monocytes through the cell cycle. Unexpectedly, we found that Nr4a1 −/− bone marrow had approximately threefold more Ly6C − monocytes in S phase and twofold more Ly6C − monocytes in G2 phase than did wild-type control bone marrow (Fig. 6a,b) . To assess potential DNA damage in the abnormally dividing Ly6C − monocytes, we examined phosphorylation of histone H2AX at Ser139, a marker used to identify double-stranded DNA breaks during progression through the cell cycle. 
A r t i c l e s
We found evidence of greater DNA damage in Nr4a1 −/− Ly6C − monocytes that were in S or G2 phase than in their wild-type counterparts (Fig. 6c,d) . Transcripts of the S-phase mediators cyclin A2 and Cdk1 were about twofold greater in abundance in Ly6C − monocytes from Nr4a1 −/− bone marrow than in those from wild-type bone marrow (Fig. 6e) , which indicated an acceleration of entry into the cell cycle. Consistent with that, expression of the transcription factor E2F2, which represses entry into S phase, was about 45% lower in Ly6C − monocytes from Nr4a1 −/− mice than in those from wild-type mice (Fig. 6e) . We observed no difference in the cell-cycle progression of Ly6C + monocytes or other cells in Nr4a1 −/− bone marrow (data not shown). Thus, in Ly6C − monocytes, NR4A1 is required for progression through the cell cycle during bone marrow differentiation.
Nr4a1 −/− Ly6C − monocytes die in the bone marrow To determine the nature of the defect in monocyte production and cell-cycle arrest, we measured apoptosis of Ly6C + and Ly6C − populations in wild-type and Nr4a1 −/− mice. Annexin V and propidium iodide staining of monocyte populations in bone marrow, blood and spleen showed that Nr4a1 −/− bone marrow had significantly more apoptotic and dead Ly6C − monocytes than did wild-type bone marrow (Fig. 7a,b) . Approximately twofold more apoptotic and dead Ly6C − monocytes were present in Nr4a1 −/− bone marrow than in wild-type control bone marrow (Fig. 7a,b) . Additionally, we observed higher expression of cleaved caspase-3, another hallmark of apoptosis, in Ly6C − monocytes obtained from Nr4a1 −/− bone marrow than in monocytes from wild-type control bone marrow (Fig. 7c,d) . We found no three (a,b,e) or two (c,d) experiments (mean and s.e.m. in a-c,e) . alteration in the annexin V staining of Ly6C − monocytes in the blood or spleen (Fig. 7a) , which suggested that the Ly6C − monocytes or their precursors underwent apoptosis and death in the bone marrow before they were able to egress to blood. We did not observe alterations in the apoptosis of myeloid progenitor populations in Nr4a1 −/− bone marrow (Fig. 7e) , which suggested that apoptosis occurs during monocyte maturation after the MDP stage. Notably, we did not observe apoptosis of Ly6C + monocytes in Nr4a1 −/− bone marrow (Fig. 7a) , which indicated that in the steady state, NR4A1 expression is not critical for the differentiation or survival of Ly6C + monocytes.
Phenotype of Ly6C − monocytes in Nr4a1 −/− mice Next we measured the expression of mRNA for factors known to be important for monocyte and macrophage differentiation. We found significantly lower expression of CX3CR1 (70% lower), C/EBP-β (90% lower) and JunB (70% lower) in Nr4a1 −/− Ly6C − monocytes than in their wild-type control counterparts (Fig. 8) , which suggested less differentiation potential of the Ly6C − subset. PU.1 expression was not significantly different in Nr4a1 −/− Ly6C − monocytes versus wild-type control Ly6C − monocytes. Moreover, Nr4a1 −/− Ly6C − monocytes had more activation of the transcription factor NF-κB than did Nr4a1 +/+ Ly6C − monocytes (Supplementary Fig. 6 ), which suggested alterations in the inflammatory phenotype of this monocyte subset in the absence of NR4A1. At the protein level, the expression of CX3CR1 and CCR2 in Ly6C − monocytes from Nr4a1 −/− bone marrow was also lower than that in Ly6C − monocytes from wild-type bone marrow (Fig. 8a) . Notably, the surface expression of CX3CR1 and CCR2 in Nr4a1 −/− Ly6C + monocytes was similar to that on wild-type monocytes. Expression of CD11a (LFA-1), an integrin that is important for the patrolling function of Ly6C − monocytes, was about 60% lower in Ly6C − monocytes and 30% lower in Ly6C + monocytes from Nr4a1 −/− mice than in their counterparts from wild-type mice (Fig. 8a) . Thus, Ly6C − monocytes in Nr4a1 −/− bone marrow did not express phenotypic markers consistent with normal, differentiated Ly6C − monocytes, in further support of the proposal of impaired differentiation of this monocyte subset in the absence of NR4A1.
DISCUSSION
In this study we have shown that mice deficient in NR4A1 had a defect in bone marrow production of Ly6C − monocytes and, as a consequence, these mice lacked mature Ly6C − monocytes circulating in the blood and spleen and patrolling the vascular endothelium. The loss of this subset in the absence of NR4A1 was probably due to an intrinsic defect in hematopoietic cell differentiation. Resident MDP populations in the bone marrow and DC populations in the spleen were unaffected by the absence of NR4A1, which suggested a specific role for NR4A1 in mediating monocyte differentiation. The few Ly6C − monocytes that remained in the bone marrow in the absence of NR4A1 seemed unable to proliferate and differentiate properly; they were larger than Ly6C − monocytes from control mice and had lower expression of CX3CR1, CCR2 and CD11a (LFA-1). Nr4a1 −/− Ly6C − monocytes also accumulated in S phase of the cell cycle, although they were unable to complete cell division, and underwent apoptosis during phases S and G2 of the cell cycle. Thus, our data have shown that NR4A1 functions in the bone marrow as a critical transcription factor required for the production of monocytes, particularly those of the Ly6C − subset.
Lower expression of the transcription factor E2F2, which is considered a critical repressor for cell commitment to S phase 44 , may have been partially responsible for the premature entry into and lack of completion of S-phase cycling observed for Nr4a1 −/− Ly6C − monocytes. Published findings showing that E2F family members are required for the survival of myeloid cells and their ability to respond properly to colony-stimulating factor 1 signals 45 are consistent with our observations. The finding that NR4A1 may regulate cell-cycle progression in monocytes is perhaps not unexpected given that studies have shown that the closely related member of the NR4A family, NR4A2, has a similar regulatory role in maintaining the quiescence of hematopoietic stem cells through associated upregulation of cell-cycle inhibitors 26 . Our finding of higher expression of NR4A2 in MDPs, the precursor that has been identified as being closest to monocyte populations, indicates that NR4A2 may regulate the homeostasis of monocytic and DC precursor populations. Upregulation of the cellcycle initiators cyclin A2 and Cdk1 in Nr4a1 −/− monocytes indicated that NR4A1 may have a similar role in maintaining the production of Ly6C − and possibly Ly6C + monocytes.
An alternative explanation for our findings is that NR4A1 may act as a survival and/or differentiation factor in Ly6C − monocytes by encouraging the expression of receptors important for monocyte A r t i c l e s function, such as CX3CR1. CX3CR1 has been identified as a factor important for the survival of Ly6C − monocytes 46 . However, the absence of CX3CR1 or its ligand CX3CL1 in mice results in only modestly fewer Ly6C − blood monocytes under steady-state and inflammatory conditions 46, 47 . The relationship between NR4A1 and the potential monocyte-survival factor CX3CR1 is uncertain, as are the identities of additional factors that drive the survival and differentiation of Ly6C − monocytes. Our data suggest that the defect in monocyte production in Nr4a1 −/− mice is more probably upstream of CX3CR1, as Nr4a1 −/− mice had fewer Ly6C − monocytes in the bone marrow, whereas CX3CR1-deficient mice do not 46 .
Although it is accepted that both monocyte subsets arise from a common MDP in the bone marrow 47 , the molecular control of their differentiation and the putative intermediates between MDPs and mature monocyte subsets have remained unclear. Specifically, whether Ly6C − monocytes differentiate directly from a bone marrow progenitor or from the conversion of mature Ly6C + monocytes has been a matter of debate. Although mature monocytes recirculate in the bone marrow 40 , our data do not support the proposal that mature Ly6C + monocytes convert into Ly6C − monocytes in the peripheral blood. Instead, our findings suggest that the precursor of Ly6C − monocytes is an immature proliferating cell.
Under conditions of competitive bone marrow transplantation, both Ly6C + and Ly6C − monocyte subsets were diminished in the absence of NR4A1. Given that irradiation and reconstitution inevitably enhance inflammation, it is possible that stress or inflammatory factors resulted in NR4A1-mediated regulation of the Ly6C + and Ly6C − monocyte populations. Expression of NR4A1 was present but low in Ly6C + monocytes and probably had some role in Ly6C + monocyte function. Notably, activation of the NF-κB pathway, a pathway important for the regulation of inflammation, was greater in both populations of monocytes from Nr4a1 −/− bone marrow. Active NR4A1-binding sites have been identified on the promoter of the gene encoding the NF-κB-inhibitory regulator IκBα and have been suggested as a means of downregulating NF-κB inflammatory signaling 48 . Such findings suggest that in both Ly6C + and Ly6C − monocytes, NR4A1 has an important role in regulating NF-κB-mediated inflammatory responses and that the absence of NR4A1 may lead to an exaggerated inflammatory response 11 .
Inflammation also leads to substantially more circulating monocytes 30, 49 . NR4A1 is well known to rapidly respond to early inflammatory events and may partially drive monocyte proliferation and/or extravasation. Ly6C − monocytes have been observed to extravasate and respond rapidly 32, 38, 47 in a time frame very similar to that of NR4A1 induction in response to early inflammation 11 . However, inflammation would probably not overcome the defect in production of the Ly6C − monocyte subset in Nr4a1 −/− mice. One example of this is the finding that irradiation of Nr4a1 −/− mice did not correct the impaired production of the Ly6C − subset in our studies. However, inflammation may indeed modulate the number of Ly6C + monocytes and may also influence the functions of both monocyte subsets. This may vary depending on the type or model of inflammation studied. Further research is needed to understand exactly how NR4A1-mediated signaling pathways are involved in regulating both monocyte-subset differentiation and the specific function of these monocyte subsets in disease.
In summary, we have identified NR4A1 as a critical regulator of monocyte homeostasis in the bone marrow. Deletion of NR4A1 from hematopoietic cells led to loss of monocytes in vivo, particularly of the Ly6C − subset. Thus, NR4A1-mediated signaling pathways may be key targets for the development of therapeutics to regulate monocyte differentiation and function to control early inflammatory events in disease.
METHODS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/natureimmunology/.
Note: Supplementary information is available on the Nature Immunology website.
